Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 19:36:37时区推断·⟳ 抓取 19:37:29·⚡ 决策 07-22 19:44:10 +6m41s·97.0 天前
Zoetis 在加拿大和欧盟商业化推出猫骨关节炎三个月止痛疗法 Portela
Portela 单针最长三个月缓解猫骨关节炎疼痛，较 Zoetis 既有月度产品 Solensia 有给药频次差异。
📄 原文Investing.com↗ 原文
Zoetis launches three-month osteoarthritis pain therapy for cats
+61% upside, this growing AI-picked healthcare leader is trading at 52-week lows PARSIPPANY, N.J. - Zoetis Inc. (NYSE:Z…
不做 Zoetis（ZTS.US）
大市值主标的的区域产品发布未披露价格、峰值销售或利润指引，且存在自家 Solensia 替代效应，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- Zoetis 宣布 Portela 在加拿大和欧盟商业化上市，适用于猫骨关节炎疼痛。市场反应:ZTS.US 最新价 75.35 美元，较前收跌 1.12%。
关键理由
- Portela 单针最长三个月缓解猫骨关节炎疼痛，较 Zoetis 既有月度产品 Solensia 有给药频次差异。
- 公司称猫骨关节炎影响最高 40% 猫群但仅 18% 被兽医诊断，潜在市场存在但真实渗透率仍需验证。
- ZTS.US 市值约 315.9 亿美元，区域商业化发布未披露价格、销售指引或利润增量，短线相对市值弹性不足。
主要风险
- Portela 与自家 Solensia 可能存在替代而非纯增量；标签不良反应包括注射痛和皮肤问题。
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,924 字
+61% upside, this growing AI-picked healthcare leader is trading at 52-week lows
PARSIPPANY, N.J. - Zoetis Inc. (NYSE:ZTS) announced today the commercial launch of Portela (relfovetmab) in Canada and European Union member states, according to a press release statement. The product is an anti-nerve growth factor monoclonal antibody therapy designed to alleviate osteoarthritis pain in cats for up to three months with a single subcutaneous injection.
Portela targets nerve growth factor, a mediator of pain and inflammation. A nine-month European field study showed improvements in osteoarthritis pain as early as three days after the first injection.
Osteoarthritis affects up to 40% of cats, but only 18% of affected cats are diagnosed with the condition by veterinary professionals, according to the company. Cats naturally mask pain, and owners often interpret reduced activity as normal aging rather than a treatable condition.
The most common side effect reported in the EU product label is immediate pain upon injection, occurring in more than one in 10 cats treated, followed by dermatitis in one to 10 cats per 100 treated. Uncommon side effects included pruritus, skin scabs, injection site swelling and injection site hair loss. In Canada, possible side effects include injection site pain, skin infection, hair loss and dermatitis, and decreased appetite.
Portela should not be used in cats with known hypersensitivity to relfovetmab, or breeding, pregnant or lactating cats, or cats less than 12 months of age. The therapy is administered under veterinary guidance.
Zoetis previously launched Solensia (frunevetmab), a monthly anti-nerve growth factor monoclonal antibody for feline osteoarthritis pain. Portela binds to a different site on nerve growth factor to provide longer-lasting pain relief.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
PARSIPPANY, N.J. - Zoetis Inc. (NYSE:ZTS) announced today the commercial launch of Portela (relfovetmab) in Canada and European Union member states, according to a press release statement. The product is an anti-nerve growth factor monoclonal antibody therapy designed to alleviate osteoarthritis pain in cats for up to three months with a single subcutaneous injection.
Portela targets nerve growth factor, a mediator of pain and inflammation. A nine-month European field study showed improvements in osteoarthritis pain as early as three days after the first injection.
Osteoarthritis affects up to 40% of cats, but only 18% of affected cats are diagnosed with the condition by veterinary professionals, according to the company. Cats naturally mask pain, and owners often interpret reduced activity as normal aging rather than a treatable condition.
The most common side effect reported in the EU product label is immediate pain upon injection, occurring in more than one in 10 cats treated, followed by dermatitis in one to 10 cats per 100 treated. Uncommon side effects included pruritus, skin scabs, injection site swelling and injection site hair loss. In Canada, possible side effects include injection site pain, skin infection, hair loss and dermatitis, and decreased appetite.
Portela should not be used in cats with known hypersensitivity to relfovetmab, or breeding, pregnant or lactating cats, or cats less than 12 months of age. The therapy is administered under veterinary guidance.
Zoetis previously launched Solensia (frunevetmab), a monthly anti-nerve growth factor monoclonal antibody for feline osteoarthritis pain. Portela binds to a different site on nerve growth factor to provide longer-lasting pain relief.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。